Use of Alzheimer's disease marker

A technology for Alzheimer's disease and markers, applied in the field of detection, can solve the problems of invasive diagnostic sampling limitations and low detection costs, and achieve good market prospects, low detection costs, and convenient sampling

Inactive Publication Date: 2016-02-24
THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA
View PDF5 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] In view of this, the purpose of the present invention is to provide the reagents for determining the markers of Alzheimer's disease in the preparation of a test k

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of Alzheimer's disease marker
  • Use of Alzheimer's disease marker
  • Use of Alzheimer's disease marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] A total of 70 samples were selected for analysis, including 50 cases of AD and 20 cases of non-AD patients as the control group, and then statistical analysis was carried out on the basic information, including age, gender and educational background.

[0023] 1. Age normal distribution test

[0024] The normal distribution test showed that the age was normally distributed. The mean value of the AD group was 76.42±8.88, and the mean value of the control group was 77.00±7.46. Using independent t-test, there was no significant difference, p=0.801, indicating that the AD group and the control group were age-matched.

[0025] 2. Sex ratio Pearsonchi-square test

[0026] The gender ratio was tested by Pearsonchi-square, which showed that the AD group and the control group had p=0.476, and there was no significant difference, indicating that the AD group and the control group were gender-matched.

[0027] 3. Chi-square test of education composition ratio

[0028] The educat...

Embodiment 2

[0032] Using xMAP technology, also known as liquid phase chip technology (xMAP technology is one of the core technologies of Luminex high-throughput protein analysis and detection technology) to detect 21 serum proteins included in the analysis samples in peripheral blood.

[0033] Specific steps are as follows:

[0034] (1) Coded magnetic beads: Polystyrene microspheres with a diameter of 5.6 μm were dyed into different fluorescent colors with two red fluorescent dyes in different ratios, so as to obtain up to 100 kinds of fluorescent coded microspheres;

[0035] (2) Covalent cross-linking: The antibody molecules against 21 serum proteins are bound to specific coded microspheres by covalent cross-linking, and each coded microsphere corresponds to the corresponding detection item; The serum antibodies of 21 kinds of cytokines labeled with the ball were purchased from Merk Company.

[0036] (3) Binding reaction: Mix the fluorescently encoded microspheres for different analytes...

Embodiment 3

[0048] In order to further verify that the 6 factors screened in Example 2 have potential diagnostic value, the specificity, sensitivity, area under the curve (Area Under the Curve, AUC) value and cutoff value of each factor were analyzed statistically to establish risk prediction model.

[0049] The ROC curves of IL-12(p40) and IL-12(p70) are as follows figure 2 shown. The results showed that the AUC values ​​of IL-12(p40) and IL-12(p70) were 0.66 and 0.68, respectively, and the corresponding 95% confidence intervals were 0.5287-0.7948 and 0.5425-0.8178; IL-12 and IL-17 There was no statistically significant difference in the AUC values ​​of the two indicators, p=0.8470.

[0050]The ROC curve of IL-7 is as follows image 3 shown. The results showed that the AUC value of IL-7 was 0.6820, and its 95% confidence interval was 0.5305-0.8335.

[0051] The ROC curve of sCD40L is as follows Figure 4 shown. The results showed that the AUC value of sCD40L was 0.8263, and its 9...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Login to view more

Abstract

The invention discloses a use of a reagent for measuring an Alzheimer's disease (AD) marker in preparation of a kit for detecting a tested object suffering from Alzheimer's disease, wherein the Alzheimer's disease marker is at least one of IL-12 (P40), IL-12 (P70), VEGF, sCD40L, GRO and IL-7, and a new blood marker is provided for diagnosis or differential diagnosis of Alzheimer's disease. The invention also provides the kit for combined detection of the VEGF marker and the sCD40L marker; especially for senile patients, the kit is convenient to use, has the characteristics of no invassiveness and low test cost, can directly perform peripheral blood tests, has no need of collection of cerebrospinal fluid, relieves patient sampling pain, also has the advantages of good specificity, high sensitivity and good clinical diagnostic value, and lays a foundation for realization of hematology diagnosis of AD.

Description

technical field [0001] The invention belongs to the detection field, and specifically relates to the use of Alzheimer's disease markers in the preparation of a test kit for detecting Alzheimer's disease in subjects, where the Alzheimer's disease marker is IL-12 (P40), At least one of IL-12(P70), VEGF, sCD40L, GRO, and IL-7. Background technique [0002] Alzheimer's disease (Alzheimer's Disease, AD) has gone through a century from its discovery to in-depth research, but due to the lack of preclinical diagnosis methods and effective treatment methods, it is the only one of the ten deadly diseases that cannot be diagnosed at present. The harm of a disease that prevents, cures or delays its course has been raised as a global public health problem. At present, the diagnosis of AD is still limited to relevant clinical intelligence assessments such as the Minimum Mental State Examination (MMSE) combined with PET or MRI, as well as amyloid Aβ and phosphorylated tau protein P-tau in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/68G01N21/64
CPCG01N33/6896G01N21/6402
Inventor 余抒府伟灵刘跃平刘璐
Owner THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap